Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of Your #1 4\u00d74 SUVs - 2Best Wellness Tracker Keep You On target
- 3Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- 4ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- 5Careful Connections: Building Association and Trust
- Doggie diversity in size and shape began at least 11,000 years ago
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- France's Senate backs ban on social media platforms for under-15s
- What to know about new CDC deputy director who has been critical of COVID vaccines
- Understanding the Rudiments of Tree Administrations
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- Everyday Seasonal Positions That Compensate Fairly in the US
- Historical mysteries solved by science in 2025
